1. Methylation Dynamics on 5′-UTR of DAT1 Gene as a Bio-Marker to Recognize Therapy Success in ADHD Children
- Author
-
Valentina Carpentieri, Gabriella Lambacher, Miriam Troianiello, Mariangela Pucci, Diana Di Pietro, Giovanni Laviola, Claudio D’Addario, Esterina Pascale, and Walter Adriani
- Subjects
dopamine transporter (DAT1) gene ,attention-deficit/hyperactivity disorder (ADHD) ,problematic children ,CpGs methylation pattern ,methylphenidate (MPH) ,cognitive-behavioral therapy (CBT) ,Pediatrics ,RJ1-570 - Abstract
Attention-deficit/hyperactivity disorder (ADHD), a neuropsychiatric condition characterized by inattention, hyperactivity, and impulsivity, afflicts 5% of children worldwide. Each ADHD patient presents with individual cognitive and motivational peculiarities. Furthermore, choice of appropriate therapy is still up to clinicians, who express somewhat qualitative advice on whether a child is being successfully cured or not: it would be more appropriate to use an objective biomarker to indicate whether a treatment led to benefits or not. The aim of our work is to search for such clinical biomarkers. We recruited 60 ADHD kids; psychopathological scales were administered at recruitment and after six weeks of therapy. Out of such a cohort of ADHD children, we rigorously extracted two specific subgroups; regardless of the initial severity of their disease, we compared those who obtained the largest improvement (ΔCGAS > 5) vs. those who were still characterized by a severe condition (CGAS < 40). After such a therapy, methylation levels of DNA extracted from buccal swabs were measured in the 5′-UTR of the DAT1 gene. CpGs 3 and 5 displayed, in relation to the other CpGs, a particular symmetrical pattern; for “improving” ADHD children, they were methylated together with CpG 2 and CpG 6; instead, for “severe” ADHD children, they accompanied a methylated CpG 1. These specific patterns of methylation could be used as objective molecular biomarkers of successful cures, establishing if a certain therapy is akin to a given patient (personalized medicine). Present data support the use of post-therapy molecular data obtained with non-invasive techniques.
- Published
- 2023
- Full Text
- View/download PDF